Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Polymyxin E Recombinant Mouse Monoclonal Antibody (1E6)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
图: 1 / 1
Polymyxin E Antibody (MA566360) in SDS-PAGE
SDS-PAGE characterization of Polymyxin E under reducing conditions. Lane M: Protein marker (kDa); Lane PME: Purified Polymyxin E Recombinant Monoclonal (Product # MA566360). Polymyxin E showing heavy chain (~50 kDa) and light chain (~25 kDa). Gels were stained with Coomassie Brilliant Blue R-448.
产品信息
MA566360
产品规格
种属反应
Chemical
宿主/亚型
Mouse
/ IgG
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
克隆号
1E6
抗原
Conjugate of PME hapten and KLH.
偶联物
形式
Liquid
浓度
7 mg/mL
纯化类型
Protein G
保存液
PBS
内含物
0.09% sodium azide
保存条件
-20°C
运输条件
Ambient (domestic); Wet ice (international)
靶标信息
Polymyxin E, also known as colistin, is a cyclic polypeptide antibiotic produced by the bacterium Aerobacillus polyaerogenes. It is synthesized through a nonribosomal peptide synthetase (NRPS) gene cluster, which incorporates amino acids such as L-2,4-diaminobutyric acid, L-leucine, and L-threonine. The gene cluster responsible for its biosynthesis has been characterized using genomic libraries and PCR-based screening. Structurally, polymyxin E is a branched cyclic decapeptide with hydrophobic modifications that enhance its activity against Gram-positive and Gram-negative bacteria. Functionally, it acts as a last-resort antibiotic for treating multidrug-resistant Gram-negative bacterial infections, although its effectiveness can be compromised by plasmid-mediated resistance. Recent studies have focused on enhancing its efficacy through synergistic partners and structural modifications.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
